Nkarta is headquartered in South San Francisco, California.
Nkarta disclosed revenue of 132M USD for 2023 and 119M USD for 2022.
Nkarta has 110 employees.
Nkarta is a life science company.
Nkarta was founded in 2015.
1150 Veterans Boulevard,
South San Francisco, California
94080
United States,
(925) 407-1049
www.nkartatx.com
Nkarta is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage. Nkarta Therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated, and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. Nkarta was founded on the proprietary, robust, and well-characterized natural killer (NK) cell expansion technology pioneered by Dario Campana. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta was formed in 2015 and is based in South San Francisco, California.
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
